R
96.31
-1.02 (-1.05%)
| Penutupan Terdahulu | 97.33 |
| Buka | 97.84 |
| Jumlah Dagangan | 1,431,551 |
| Purata Dagangan (3B) | 3,378,436 |
| Modal Pasaran | 18,618,630,144 |
| Harga / Jualan (P/S) | 9.04 |
| Harga / Buku (P/B) | 4.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| EPS Cair (TTM) | -4.01 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.46% |
| Nisbah Semasa (MRQ) | 13.46 |
| Aliran Tunai Operasi (OCF TTM) | -591.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -349.13 M |
| Pulangan Atas Aset (ROA TTM) | -23.09% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.68% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Revolution Medicines, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.30 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.02% |
| % Dimiliki oleh Institusi | 105.87% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 170.00 (Stifel, 76.51%) | Beli |
| Median | 144.00 (49.52%) | |
| Rendah | 120.00 (Piper Sandler, 24.60%) | Beli |
| Purata | 143.78 (49.29%) | |
| Jumlah | 9 Beli | |
| Harga Purata @ Panggilan | 108.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 145.00 (50.56%) | Beli | 102.15 |
| Piper Sandler | 26 Feb 2026 | 120.00 (24.60%) | Beli | 102.15 |
| Wells Fargo | 26 Feb 2026 | 144.00 (49.52%) | Beli | 102.15 |
| JP Morgan | 02 Feb 2026 | 122.00 (26.67%) | Beli | 97.16 |
| Oppenheimer | 27 Jan 2026 | 150.00 (55.75%) | Beli | 99.82 |
| Stifel | 22 Jan 2026 | 170.00 (76.51%) | Beli | 118.81 |
| RBC Capital | 21 Jan 2026 | 140.00 (45.36%) | Beli | 117.53 |
| Guggenheim | 20 Jan 2026 | 160.00 (66.13%) | Beli | 116.22 |
| Mizuho | 13 Jan 2026 | 143.00 (48.48%) | Beli | 119.95 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ANDERS JACK | 102.02 | - | 20,200 | 2,060,804 |
| ANDERSON ELIZABETH M | 101.19 | 101.19 | 0 | 0 |
| CISLINI JEFF | 102.02 | - | 14,500 | 1,479,290 |
| GOLDSMITH MARK A | 102.02 | 101.62 | 21,100 | 2,167,022 |
| HORN MARGARET A | 102.02 | - | 21,100 | 2,152,622 |
| KELSEY STEPHEN MICHAEL | 102.02 | - | 21,100 | 2,152,622 |
| WANG XIAOLIN | 102.02 | - | 15,100 | 1,540,502 |
| WEI LIN | 102.02 | - | 15,100 | 1,540,502 |
| Jumlah Keseluruhan Kuantiti Bersih | 128,200 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 13,093,364 | |||
| Purata Pembelian Keseluruhan ($) | 101.92 | |||
| Purata Jualan Keseluruhan ($) | 101.48 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ANDERSON ELIZABETH M | Pengarah | 04 Mar 2026 | Dibuang (-) | 15,000 | 101.19 | 1,517,850 |
| ANDERSON ELIZABETH M | Pengarah | 04 Mar 2026 | Diperolehi (+) | 15,000 | 101.19 | 1,517,850 |
| GOLDSMITH MARK A | Pegawai | 02 Mar 2026 | Jual automatik (-) | 30,000 | 101.62 | 3,048,600 |
| GOLDSMITH MARK A | Pegawai | 02 Mar 2026 | Jual (-) | 6,000 | 101.62 | 609,720 |
| GOLDSMITH MARK A | Pegawai | 02 Mar 2026 | Pelaksanaan pilihan | 30,000 | - | - |
| ANDERS JACK | Pegawai | 01 Mar 2026 | Diperolehi (+) | 20,200 | 102.02 | 2,060,804 |
| CISLINI JEFF | Pegawai | 01 Mar 2026 | Diperolehi (+) | 14,500 | 102.02 | 1,479,290 |
| HORN MARGARET A | Pegawai | 01 Mar 2026 | Diperolehi (+) | 21,100 | 102.02 | 2,152,622 |
| GOLDSMITH MARK A | Pegawai | 01 Mar 2026 | Diperolehi (+) | 57,100 | 102.02 | 5,825,342 |
| KELSEY STEPHEN MICHAEL | Pegawai | 01 Mar 2026 | Diperolehi (+) | 21,100 | 102.02 | 2,152,622 |
| WEI LIN | Pegawai | 01 Mar 2026 | Diperolehi (+) | 15,100 | 102.02 | 1,540,502 |
| WANG XIAOLIN | Pegawai | 01 Mar 2026 | Diperolehi (+) | 15,100 | 102.02 | 1,540,502 |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 |
| 29 Jan 2026 | Pengumuman | Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor |
| 08 Jan 2026 | Pengumuman | Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib |
| 05 Jan 2026 | Pengumuman | Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 18 Dec 2025 | Pengumuman | Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |